Cancer - Press Review (June 1, 2013) – Revue de presse (1 juin 2013)

[SMW]

Cancer – Press Review – Revue de Presse

Every week on http://marclacroixcancerblog.blogspot.com
Chaque semaine sur http://marclacroixcancerblog.blogspot.com




Press Review (June 1, 2013) – Revue de presse (1 juin 2013)


First-in-class cancer drug approved to fight melanoma
The US Food and Drug Administration (FDA) has approved the first
cancer drug to inhibit a protein — called MEK — that acts in a pathway
that fuels tumour growth. The drug, called Mekinist (trametinib), was
approved on 29 May for use in advanced melanomas with specific
mutations. Other MEK-targeting drugs are being studied in a wide range
of tumours, including lung and thyroid cancers.
By Heidi Ledford. In Nature.com (blog)
http://blogs.nature.com/news/2013/05/first-in-class-cancer-drug-approved-to-fight-melanoma.html

New Possibilities for Prostate Cancer Treatment Revealed
Researchers have identified a sub-group of cells that could contribute
to prostate cancer recurrence, opening up new ways to treat the
disease, which claims more than 3000 lives a year in Australia.
In Science Daily
http://www.sciencedaily.com/releases/2013/05/130529144315.htm

Barbara Brenner, breast cancer awareness advocate, dies at 61
Barbara Brenner, who directed Breast Cancer Action, a San Francisco-
based breast cancer awareness group, for 15 years, died May 10 at her
home in San Francisco. She was 61. Although she “beat the breast
cancer odds,” as she once said, Ms. Brenner resigned her post in 2010
because of amyotrophic lateral sclerosis, a degenerative nerve
disorder known as ALS.
By Valerie J. Nelson. In Washington Post
http://www.washingtonpost.com/local/obituaries/barbara-brenner-breast-cancer-awareness-advocate-dies-at-61/2013/05/29/6ae7758e-c7d5-11e2-8da7-d274bc611a47_story.html

Immunotherapy's cancer remit widens
Combination therapies hold great promise, but at what cost?
By Heidi Ledford. In Nature.com (blog)
http://www.nature.com/news/immunotherapy-s-cancer-remit-widens-1.13079


Cancer de la prostate : le Jevtana bientôt remboursé
Marisol Touraine, la ministre de la santé, a annoncé, vendredi 31 mai,
le remboursement en France du Jevtana, un traitement coûteux du groupe
Sanofi contre le cancer de la prostate. Interpellée par l'Association
nationale des malades du cancer de la prostate (Anamacap), Mme
Touraine a indiqué sur France Info que le médicament serait pris en
charge par l'assurance-maladie.
Dans Le Monde
http://www.lemonde.fr/sante/article/2013/05/31/cancer-de-la-prostate-le-jevtana-bientot-rembourse_3421747_1651302.html

La FDA donne son feu vert à 2 nouveaux traitements contre le mélanome
Deux nouvelles thérapies ciblées du mélanome métastatique inopérable
ainsi qu'un test diagnostic pour identifier le bon traitement ont reçu
une autorisation de mise sur le marché (AMM) de la Food and Drug
Administration (FDA). Les nouveaux agents, le dabrafenib (Tafinalar®)
et le trametinib (Mekinist®), ont été développés par GlaxoSmithKline.
Tous deux sont des traitements oraux mais ont des mécanismes d'action
légèrement différents.
Par Zosia Chustecka, Aude Lecrubier. Dans Medscape
http://www.medscape.fr/oncologie/articles/1545149/








Cancer Blog – Marc Lacroix – Le Blogue du Cancer
http://marclacroixcancerblog.blogspot.com













Marc Lacroix-Corman – InTextoResearch – Baelen (06/2013)